Nymox Pharmaceutical Corporation
NYMXF
$0.1364
$0.026424.00%
OTC PK
| 09/30/2024 | 12/31/2023 | 09/30/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | 51.60% | -44.06% | -44.06% | -49.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 25.64% | -83.69% | -83.69% | -82.37% |
| Operating Income | -- | -25.64% | 83.70% | 83.70% | 82.38% |
| Income Before Tax | -- | -34.49% | 39.46% | 39.46% | 45.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -34.49% | 39.46% | 39.46% | 45.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -34.49% | 39.46% | 39.46% | 45.94% |
| EBIT | -- | -25.64% | 83.70% | 83.70% | 82.38% |
| EBITDA | -- | -29.19% | 83.52% | 83.52% | 82.66% |
| EPS Basic | -- | -27.95% | 42.86% | 42.86% | 49.79% |
| Normalized Basic EPS | -- | -21.61% | 42.93% | 42.93% | 49.79% |
| EPS Diluted | -- | -19.32% | 43.51% | 43.51% | 45.54% |
| Normalized Diluted EPS | -- | -18.11% | 44.26% | 44.26% | 50.74% |
| Average Basic Shares Outstanding | -- | 2.31% | 3.22% | 3.22% | 5.21% |
| Average Diluted Shares Outstanding | -- | -1.82% | -1.00% | -1.00% | 0.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |